What You Should Know:
Wellin5, the premier provider of online counseling, proudly announces a new partnership with Kintsugi, an AI mental health technology leader.This collaboration comes at a time when Wellin5 has successfully navigated the turbulent economic landscape and challenges in the health tech space to thrive and bring this vital partnership to life, setting a new standard in mental health care for over 50,000 clients based in Canada and the USA.
Revolutionizing
Read More
Biomarkers| Big Data| News, Analysis, Insights - HIT Consultant
Debiopharm and ThinkingNodeLife.ai Partner on AI-Driven Cancer Drug Development
What You Should Know:
- Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.
- This strategic partnership combines Debiopharm's deep pharmaceutical expertise with TNL's revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.
Unlocking the Hidden Potential of a
Read More
23andMe Launches Health Action Plan Based on Genetic/Health Data
What You Should Know:
- 23andMe, a genetic health and biopharmaceutical company launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options.
- Health Action Plan is a helpful first step when it comes to prevention and early risk detection. It offers customers specific actions and
Read More
The Future of Biomarker-Based Therapy for Mental Disorder Care
We are living in a mental health epidemic. An estimated 26 percent of Americans ages 18 and older – about one in four adults – suffer from a diagnosable mental disorder in a given year. Among mental disorders, cases of PTSD are on the rise. Roughly five percent of American adults suffer from PTSD in any given year and more than 13 million Americans reported PTSD in 2020 – most of whom are women. Standard PTSD treatments most often come in the form of pharmacotherapy or psychotherapy and include
Read More
Mount Sinai Researchers Identify Biomarker That Tracks Recovery From Treatment-Resistant Depression
What You Should Know:
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More
ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection
What You Should Know:
- ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT).
- ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More
Philips & DoD Ink $10M Deal for AI-Wearable Disease Detection
What You Should Know:
The Department of Defense and Philips announced a $10M award to expand the readiness of our service members with the Rapid Assessment of Threat Exposure (RATE) AI wellness tool.The first group in this new cohort are theAir Force First Sergeants, who are responsible for overall squadron health and wellness.RATE is an AI algorithm, trained on clinical data from hospital-acquired infections to work with any off-the-shelf wearable to detect possible infection, acting
Read More
PsychoGenics Launches AI Platform to Revolutionize Drug Discovery
What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Accenture: Data Collaboratives Hold Great Promise for Accelerated Healthcare Progress and Precision Medicine
What You Should Know:
- Accenture published Fast-Forwarding Healthcare through Data Collaboratives Report to discover how best health ecosystem players access data to fast-forward healthcare.
- Data generated by technical and scientific advances, like connected health devices, consumer health and medical-grade digital apps, individual multi-omics profiling data and the move to cloud storage, holds great promise for accelerated healthcare progress and precision medicine, and data
Read More
